What guidance did FMC's management provide for the next earnings period?

What does FMC do and what are its main business segments?

What factors drove the changes in FMC's revenue and profit?

What were the key takeaways from FMC’s earnings call?

What were the key takeaways from FMC's earnings call?

What is FMC's gross profit margin?

What is the market's earnings forecast for FMC next quarter?

Did FMC beat or miss consensus estimates last quarter?

- **Strategic Review Launched**: Board authorizes exploration of potential company sale alongside $1B debt reduction plan via asset sales/licensing.
- **Core Portfolio Challenges**: 2026 EBITDA headwinds from high-cost manufacturing ($1B sales transition), offset by 2027+ cost reductions and new actives growth.
- **Rynaxypyr Resilience**: Branded earnings flat YoY via advanced formulations, despite partner sales decline and generic competition.
- **New Actives Growth**: 2026 sales $300-400M (vs. $200M in 2025), driven by fluindypyr and Isoflex, with long-term $2B+ potential.
- **Financial Tightrope**: 2026 EBITDA guidance $670-730M (-12%), with Q1 EBITDA at $45-50M (-58%) due to tariffs and manufacturing costs.

**【CEO Strategic Priorities】**
- Announced strategic review process to explore potential sale of the company, alongside debt reduction plan targeting $1 billion through asset sales (e.g., India commercial business) and licensing agreements.
- Focused on improving competitiveness of core portfolio (excluding Rynaxypyr) by reducing manufacturing costs by 35% by 2027, despite expected 2026 sales headwinds.
- Rynaxypyr post-patent strategy: branded earnings expected flat YoY, with price reductions offset by volume growth in advanced formulations.
- New active ingredients (fluindypyr, Isoflex, Dodhylex) projected to grow from $200M in 2025 to $300-400M in 2026, with long-term $2B+ target by 2035.

**【CFO Financial Update】**
- Q4 2025: Sales $1.08B (-11% YoY), adj. EBITDA $280M (-17% YoY), adj. EPS $1.20 (-33% YoY) due to pricing pressure and higher interest.
- 2026 Guidance: Sales $3.6-3.8B (-5% midpoint vs. 2025), adj. EBITDA $670-730M (-12% midpoint). Q1 2026 EBITDA expected $45-50M (-58% YoY) due to tariffs and manufacturing costs.
- Free cash flow projected breakeven (-$65M to +$65M) with $130M restructuring spend, targeting 0.5x net debt reduction by year-end.

**【Q&A Highlights】**
- **Strategic Alternatives**: CEO emphasizes dual-track approach (base plan + potential sale) to maximize shareholder value, noting Board support for proactive review process.
- **Product Performance**: Confidence in new actives growth (fluindypyr registrations complete, Isoflex delayed U.K. sales), but caution on core portfolio execution risks.
- **Debt Management**: CFO details $500M bond refinancing plans and covenant compliance, with focus on reducing leverage to 4.1x (2025) → 3.6x (2026 target).

FMC Corporation (FMC) Q4 2025 Earnings Call Transcript

- **Revenue Decline**: Q3 revenue down 49% YoY to $542 million, driven by India inventory corrections and generic competition.
- **EBITDA Improvement**: Adjusted EBITDA up 17% YoY to $236 million, supported by cost control and new product growth.
- **Dividend Cut**: Quarterly dividend reduced to $0.08/share, freeing $250 million annually for debt repayment.
- **India Sale**: Business valued at $450 million with strong buyer interest, expected to close by year-end.
- **Generic Pressure**: 6% price decline and 2% volume growth in core portfolio, offset by new product demand.

**【CEO Summary Section】**
- Q3 revenue declined 49% year-over-year to $542 million, primarily due to channel inventory corrections in India and pricing pressures from generics in Latin America.
- Excluding India, revenue fell 4% YoY to $961 million, driven by a 6% price decline and 2% volume growth.
- Adjusted EBITDA was $236 million, up 17% YoY, with margin improvement from cost control and new product demand.
- India business held for sale reported negative revenue of $419 million due to inventory returns and provisions.
- 2025 full-year guidance revised: revenue $3.92-$4.02 billion, EBITDA $830-$870 million, adjusted EPS $2.92-$3.14.

**【CFO Financial Commentary】**
- GAAP net loss was $569 million, including $282 million from India inventory actions and $227 million impairment charge.
- Free cash flow guidance updated to negative $200 million to $0 for 2025, driven by working capital pressures.
- Dividend policy changed to $0.08 per share quarterly, reducing annual payout by $250 million.
- 2025 interest expense expected to remain flat at $230-$240 million.

**【Q&A Key Highlights】**
- **Free Cash Flow Dynamics**: Q4 2025 free cash flow expected to be negative $233 million, with delays in collections from Brazil cotton crop and competitive payment terms.
- **India Sale Progress**: Business valued at $450 million with strong buyer interest; process expected to conclude by end of 2025.
- **Generic Competition**: Intensified pricing pressure in Latin America and Asia, leading to 2% sales shortfall vs. prior year.
- **Manufacturing Restructuring**: Initiatives to reduce costs in Asia and Latin America, including transitioning production to lower-cost sources.
- **New Product Pipeline**: 4 new active ingredients on track to meet $250 million sales target by year-end, with Isoflex and fluindapyr showing strong demand.

FMC Corporation (FMC) Q3 2025 Earnings Call Transcript

- **India Divestment Completed**: Excluding India from 2025 guidance to focus on higher-margin growth opportunities.
- **Q2 Financial Strength**: EBITDA up 2% YoY, EPS up 15% YoY, driven by cost savings and volume growth.
- **Cost Tailwinds Accelerating**: Q3 cost savings expected to exceed Q2, with raw material and restructuring benefits.
- **Brazil Growth Engine**: Direct sales to large farmers and co-op strategies to drive branded product growth.
- **2027 Outlook Intact**: $1.2 billion EBITDA target supported by new actives and pheromones pilot.

**【CEO Opening Remarks】**
- Announced completion of key strategic objectives for the first half of 2025, positioning the company for growth in the second half.
- Highlighted the divestment of the India commercial business to reduce operational complexity and free up resources for other growth areas.
- Q2 revenue grew 1% YoY, driven by volume growth of 6%, with channel destocking completed in most regions.
- Growth portfolio (new active ingredients) delivered high single-digit revenue growth, outpacing the core portfolio.
- Full-year guidance excludes India sales, with adjusted EBITDA and EPS expected to remain flat YoY.

**【CFO Financial Commentary】**
- Q2 adjusted EBITDA: $207 million (+2% YoY), driven by lower COGS, fixed cost absorption, and restructuring savings.
- Q2 adjusted EPS: $0.69 (+15% YoY), benefiting from EBITDA growth and lower interest expense.
- Full-year free cash flow guidance: $200-400 million, down $313 million YoY due to normalized working capital and higher capex.
- Gross debt: $4.2 billion (4.8x trailing EBITDA), with covenant leverage expected to improve to 3.7x by year-end.

**【Q&A Highlights】**
- **India Divestment**: 2024 H2 sales were $140 million, with 2025 H2 forecast of $70 million. The business is expected to be sold by year-end, with proceeds used to reduce debt.
- **Cost Savings**: Q2 cost tailwinds of $69 million driven by lower raw materials, fixed cost absorption, and restructuring. Q3 cost savings are expected to be even stronger.
- **Brazil Growth**: Direct sales to large farmers in Brazil are expected to contribute to volume growth in Q3, with 35-40% of Q2 orders already booked.
- **Rynaxypyr Strategy**: Lower manufacturing costs and reduced generic competition are driving confidence in 2026-27 growth. Q4 will see first full-scale pheromones pilot in Brazil.
- **2027 Outlook**: Maintain $1.2 billion EBITDA target, driven by new actives (fluindapyr, Isoflex, Dodhylex) and plant health products.


FMC Corporation (FMC) Q2 2025 Earnings Call Transcript

- **Channel destocking on track**: Q1 sales down 14% YoY, but 35% of North American branded sales in high-value crops with limited generic risk.
- **Post-patent strategy paying off**: New tablet-based spray products to generate $200-250M in 2025, with 3 new mixtures launching in 2026.
- **Brazil growth engine**: Direct-to-grower salesforce to target corn/soybean farmers, with multi-$100M+ upside.
- **Gross profit stability**: 2025 gross profit flat vs. 2024, with improvement expected in 2026-2027 as volume growth offsets price erosion.

**【CEO Opening Remarks】**
- **Channel destocking progress**: Q1 sales declined 14% YoY, with volume down 1% as prudent selling reduced channel inventory in most regions (excluding Asia). North America sales fell 28% due to delayed orders from retailers and growers.
- **Post-patent strategy execution**: Launched low-cost generics and high-value formulations, with new products like tablet-based sprays expected to generate $200-250M in 2025. 35% of branded sales in North America are in high-value crops with limited generic substitution risk.
- **Brazil direct-to-grower expansion**: New salesforce will target large corn and soybean growers, with multi-$100M growth potential over time. Existing routes to market (sugarcane, retailers) remain unchanged.
- **Growth portfolio momentum**: New actives like [indiscernible] and [indiscernible] show strong growth, with first sales of plant health product [indiscernible] expected in Q3. 2025-2027 financial targets exclude [indiscernible] contributions but highlight long-term potential.

**【CFO Financial Highlights】**
- **Top-line performance**: Q1 revenue decline driven by 9% price drop (half due to cost-plus contract adjustments) and 4% FX headwind. Crop Protection segment outperformed with 1% YoY growth.
- **Gross margin dynamics**: Near-term pressure from price erosion offset by volume growth, with gross profit dollars expected to remain flat in 2025 before improving in 2026-2027.
- **Cost control**: Operating expenses down 5% YoY, supporting Non-GAAP EPS of $1.08 (vs. $0.95 prior year).

FMC (FMC)-1 May 25-2025 Q1 Earnings call transcript

- **2025 Correction Year**: FMC faces $200M+ headwinds from channel inventory reset, FX, and sales force investment, but positions for 2026+ growth
- **Growth Portfolio Momentum**: New AIs (fluindapyr, Isoflex) on track for $130M+ 2024 sales, targeting $600M+ by 2027
- **LATAM Transformation**: Shifting to direct-to-grower model in soybean/corn markets to counter channel consolidation
- **Rynaxypyr Strategy**: 2025 decline expected, but 2026+ growth via generics competition and new formulations
- **2027 Vision**: $5.2B sales, 23% EBITDA margin, with growth portfolio driving 30% of revenue

**【CEO Opening Remarks】**
- FMC faces challenges with elevated channel inventory in LATAM, Asia, and Canada, driven by customers reducing inventory levels amid macroeconomic uncertainty.
- Key actions in 2025: 
  1. Aggressively reduce FMC product inventory in the channel
  2. Accelerate manufacturing cost reductions for Rynaxypyr and Cyazypyr
  3. Invest in sales organization expansion to support new active ingredients (AIs) and explore new routes to market
  4. Realign portfolio into core (off-patent products) and growth (IP-protected AIs) segments
- 2025 financial impact: Lower sales due to channel correction, but positioning for 2026+ growth with $250-350M volume growth from growth portfolio

**【CFO Financial Review】**
- Q4 2024: 
  - Revenue $1.22B (-5% YoY, +7% ex-GSS divestiture)
  - EBITDA $339M (+33% YoY)
  - Adjusted EPS $2.19 (+67% YoY)
- 2025 Guidance: 
  - Sales $4.15-4.35B (flat YoY)
  - EBITDA $870-950M (+1% YoY)
  - EPS $3.26-3.70 (flat YoY)
- Key drivers: 
  - $175-200M COGS savings from restructuring
  - $65-75M FX headwind
  - $25M+ investment in sales force expansion

**【Strategy Update】**
- Growth Portfolio: 
  - New AIs (fluindapyr, Isoflex, Dodhylex) on track for $130M+ 2024 sales, targeting $600M+ by 2027
  - Plant Health (biologicals) growing at 20%+ CAGR
- Core Portfolio: 
  - Rynaxypyr expected to decline in 2025 due to generic competition, but positioned for high-single-digit growth post-2025
  - Cyazypyr benefiting from longer IP protection and new formulations
- LATAM Focus: 
  - Direct-to-grower strategy for soybean/corn markets
  - Fluindapyr addressing $3.5B soybean rust market in Brazil

**【Q&A Highlights】**
- **Rynaxypyr Outlook**: 2025 decline due to partner contract price adjustments, but 2026+ growth via new formulations and generics competition
- **LATAM Market Dynamics**: Channel consolidation forcing shift to direct sales; Brazil inventory correction expected to take 12-18 months
- **FX Risk**: 2025 EBITDA headwind of $65-75M from strong USD
- **Free Cash Flow**: $200-400M in 2025, constrained by working capital normalization
- **2027 Targets**: $5.2B sales, $1.2B EBITDA (23% margin), with growth portfolio contributing 30% of revenue

Actual																1.84	1.72	1.22	1.42	1.53	1.81	1.43	2.16	1.88	1.93	1.23	2.37	1.77	0.5	0.44	1.07	0.36	0.63	0.69	1.79	0.18	0.69	0.89	1.2
Forecast																1.7781	1.6592	1.1127	1.4551	1.5104	1.7828	1.3158	2.0008	1.7086	1.8847	1.1278	2.3334	1.7494	0.6101	0.5389	1.0821	0.3228	0.5533	0.5686	1.6024	0.0938	0.6184	0.8522	1.1961
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+3.48%	+3.66%	+9.64%	-2.41%	+1.30%	+1.53%	+8.68%	+7.96%	+10.03%	+2.40%	+9.06%	+1.57%	+1.18%	-18.05%	-18.35%	-1.12%	+11.52%	+13.86%	+21.35%	+11.71%	+91.90%	+11.58%	+4.44%	+0.33%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	1.25B	1.16B	1.08B	1.15B	1.20B	1.24B	1.19B	1.41B	1.35B	1.45B	1.38B	1.62B	1.34B	1.01B	981.90M	1.15B	918.00M	1.04B	1.07B	1.22B	791.40M	1.05B	961.30M	1.08B
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	1.24B	1.21B	1.07B	1.16B	1.17B	1.23B	1.17B	1.37B	1.29B	1.33B	1.34B	1.53B	1.42B	1.02B	1.01B	1.24B	1.01B	1.03B	1.04B	1.32B	777.46M	996.71M	1.06B	1.15B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+0.88%	-4.17%	+1.35%	-0.99%	+1.99%	+1.11%	+1.75%	+3.36%	+5.10%	+8.89%	+2.97%	+5.99%	-5.15%	-0.28%	-2.79%	-7.57%	-9.00%	+0.47%	+2.34%	-6.94%	+1.79%	+5.40%	-9.50%	-5.88%

FMC

FMC fundamentals

FMC Q4 2025 Earnings

Earnings Call

You can ask Aime

FMC

FMC fundamentals

FMC Q4 2025 Earnings

Earnings Call

FMC Earnings Call Summary for Q4/20259:00 AM on Feb 5, 2026

FMC Earnings Call Summary for Q3/20259:00 AM on Oct 30, 2025

FMC Earnings Call Summary for Q2/20259:00 AM on Jul 31, 2025

FMC Earnings Call Summary for Q1/20259:00 AM on May 1, 2025

FMC Earnings Call Summary for Q4/20245:00 PM on Feb 4, 2025

You can ask Aime